logo
Plus   Neg
Share
Email

Roche Announces FDA Approval For Expanded Use Of Venclexta - Quick Facts

Roche (RHHBY.PK) reported FDA approval for Venclexta plus Gazyva for the treatment of people with previously untreated chronic lymphocytic leukaemia. The FDA previously granted Breakthrough Therapy Designation for the combination. The company said the approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia a new treatment option.

Venclexta is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche group, in the US and commercialised by AbbVie outside of the US.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google announced a batch of renewable energy deals totaling 1.6 GW through 18 acquisitions spread across three continents. The deals are intended to "spur the construction of more than $2 billion in new energy infrastructure," the company said. Google said the deals will increase its worldwide portfolio... Beyond Meat's main competitor Impossible Foods will launch its grocery store in California on Friday. Beyond Meat Inc. (BYND), the meatless burger and sausage maker, announced the appointment of Sanjay Shah as Chief Operating Officer. Shah will assume the responsibility for Beyond Meat's global operations and production, effective September 18.
Follow RTT
>